AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS
Last updated: 23 Dec 2024
10.21608/ajps.2023.332171
Quinoline, tyrosine kinase, immunomodulators, Tubulin inhibitors, VEGFR, BCR-ABL, Hsp90, Topoisomerases
Mostafa
Aref
Mohammed
Egyptian Drug Authority (EDA), Giza, Egypt
Abeer
Mohamed
A
Egyptian Drug Authority (EDA), Giza, Egypt. Departement of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Heliopolis University, Cairo, Egypt.
Mohammed
Dahab
A
Departement of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
Mohamed Ayman
El-Zahabi
ALy
Al Mockhaim Al Daem street, Nasr 6thdistrict, Cairo Egypt
malzahaby@azhar.edu.eg
Nasr
0000-0003-4538-5840
68
2
44970
2023-09-01
2023-12-25
2023-09-01
130
158
1110-1644
2535-1958
https://ajps.journals.ekb.eg/article_332171.html
https://ajps.journals.ekb.eg/service?article_code=332171
332,171
Original Article
518
Journal
Al-Azhar Journal of Pharmaceutical Sciences
https://ajps.journals.ekb.eg/
AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS
Details
Type
Article
Created At
23 Dec 2024